Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968471 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4148214 | 1.00 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6937064 | 0.90 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6937062 | 0.90 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6925777 | 0.85 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6926737 | 0.84 | OPRD1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6935130 | 0.84 | OPRD1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6935555 | 0.84 | OPRD1 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL6925678 | 0.83 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4157535 | 0.81 | SLC6A9 (0.67) | CYP1A2CYP3A4CYP2C9HPGDOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | claimed |
| US-20250302823-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250248995-A1 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | DISC MEDICINE, INC. | 2025-08-07 | — | — | US | disclosed |
| US-20240325382-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | DISC MEDICINE, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240269132-A1 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | DISC MEDICINE INC (US) | 2024-08-15 | — | — | US | disclosed |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | DISC MEDICINE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | DISC MEDICINE, INC. | 2021-09-16 | — | — | US | disclosed |
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8183244-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | disclosed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
| EP-0983251-B1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LTD (GB) | 2004-06-23 | — | — | EP | disclosed |
| US-6514975-B1 | Tetrazoles as selective agonists for the delta opioid receptor | PFIZER INC | 2003-02-04 | — | — | US | disclosed |
| EP-0983251-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | Pfizer Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052929-A1 | ANTI-INFLAMMATORY PIPERAZINYL-BENZYL-TETRAZOLE DERIVATIVES AND INTERMEDIATES THEREOF | PFIZER LIMITED (GB) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325382-A1 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | TRMT1, AARS1, GFPT1 | CYP1A2 2356/4885CYP3A4 2122/4885CYP2C9 2392/4885 |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | CYP1A2 993/4885CYP3A4 1018/4885CYP2C9 1128/4885 |
| US-20250302823-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC PORPHYRIAS WITH GLYCINE TRANSPORT INHIBITORS | SLC10A1, GFPT1, GLS2 | CYP1A2 484/4885CYP3A4 341/4885CYP2C9 347/4885 |
| US-20240269132-A1 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | SLC16A1, SLC7A1, SLC6A9 | CYP1A2 1469/4885CYP3A4 1001/4885CYP2C9 719/4885 |
| US-20250248995-A1 | COMPOSITIONS AND METHODS FOR TREATING POLYCYTHEMIA | SLC16A1, SLC7A1, SLC6A9 | CYP1A2 1469/4885CYP3A4 1001/4885CYP2C9 719/4885 |
| US-20210283129-A1 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | GFPT1, MPST, XPNPEP1 | CYP1A2 1036/4885CYP3A4 946/4885CYP2C9 917/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | CYP1A2 993/4885CYP3A4 1018/4885CYP2C9 1128/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | CYP1A2 993/4885CYP3A4 1018/4885CYP2C9 1128/4885 |
| US-11813257-B2 | Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors | GFPT1, MPST, XPNPEP1 | CYP1A2 1036/4885CYP3A4 946/4885CYP2C9 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.